JUAN DONATE-LOPEZ

Dr. JUAN DONATE-LOPEZ

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Ophthalmology
Verified
Journal Article
Closed access
FHFrank G. Holz
Frank G. Holz
WAWinfried Amoaku
Winfried Amoaku
JDJUAN DONATE-LOPEZ
JUAN DONATE-LOPEZ
RGRobyn Guymer
Robyn Guymer
UKUlrich Kellner
Ulrich Kellner
GSGiovanni Staurenghi
Giovanni Staurenghi

1 September 2012 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
Jose M Martinez de la CasaJose M Martinez de la Casa
Jose M Martinez de la Casa
ARAurora Ruiz-Calvo
Aurora Ruiz-Calvo
FSFederico Sáenz-Francés
Federico Sáenz-Francés
JRJuan Reche-Frutos
Juan Reche-Frutos
CCCristina Calvo-Gonzalez
Cristina Calvo-Gonzalez
JGJulián García-Feijóo
Julián García-Feijóo
Purpose. To assess the effects of intravitreal ranibizumab therapy on intraocular pressure (IOP) and retinal nerve fiber (RNFL) thickness. Methods. Forty-nine eyes of 49 patients with neovascular age-related macular degeneration (AMD) treated with intravitreal ranibizumab injections and 27 fellow eyes not requiring treatment were followed for 1 year. RNFL thickness, as measured by Fourier domain optical coherence tomography, and IOP were determined pre- and postinjection. Results. After 12 months, the mean number of injections received was 4.8 ± 1.6. The incidence of IOP elevations (>5 mm Hg over baseline) observed at the time of injection was 0.4%. Baseline RNFL thickness was 105.7 ± 12.2 μm in the treatment group compared with 101.8 ± 11.6 μm in the control group (P = 0.176). At the end of follow-up, significant RNFL thinning was noted in the treatment group (100.2 ± 11.0 μm, P < 0.001), whereas no differences were found in the control group (100.5 ± 10.8 μm, P = 0.477). Conclusions. Intravitreal ranibizumab injections used to treat AMD caused a significant change in RNFL thickness after 12 months of follow-up.

18 January 2008 in Eye
Verified
Journal Article
Closed access
LALUIS ARIAS
LUIS ARIAS
FAF Armadá
F Armadá
JDJUAN DONATE-LOPEZ
JUAN DONATE-LOPEZ
JGJ García-Arumí
J García-Arumí
JGJ Giralt
J Giralt
RBR Buggage
R Buggage

1 March 2011 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
CCCristina Calvo-Gonzalez
Cristina Calvo-Gonzalez
JRJuan Reche-Frutos
Juan Reche-Frutos
JDJUAN DONATE-LOPEZ
JUAN DONATE-LOPEZ
CPCristina Fernandez Perez
Cristina Fernandez Perez
JGJulián García-Feijóo
Julián García-Feijóo

1 October 2019 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
José Ignacio Fernández-VigoJosé Ignacio Fernández-Vigo
José Ignacio Fernández-Vigo
BKBachar Kudsieh
Bachar Kudsieh
HSHang Shi
Hang Shi
PAPedro Arriola‐Villalobos
Pedro Arriola‐Villalobos
JDJUAN DONATE-LOPEZ
JUAN DONATE-LOPEZ
JFJosé Ángel Fernández‐Vigo
José Ángel Fernández‐Vigo

1 June 2015 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
NTNuria García de la Torre
Nuria García de la Torre
RFRaquel Fernández-Durango
Raquel Fernández-Durango
RGRaquel Gómez
Raquel Gómez
MFManuel Enrique Fuentes Ferrer
Manuel Enrique Fuentes Ferrer
MRManuela Roldán-Pallarés
Manuela Roldán-Pallarés
ACAlfonso L. Calle-Pascual
Alfonso L. Calle-Pascual
Purpose.: MicroRNA (miR) expression in endothelial progenitor cells (EPCs) in type 1 diabetes (DM1) and its relation with different stages of diabetic retinopathy (DR) have not been reported to date. Our aim was to analyze miR-222, miR-221, and miR-126 expression in EPCs from DM1 patients with and without DR. Methods.: We included 41 patients with DR, 35 without DR, and 38 controls. Blood was collected for flow cytometry and EPC culture. Total RNA was extracted and purified and real-time quantitative PCR was performed for miR expression in cultured EPCs. Relative changes in miR expression were analyzed with the 2−ΔΔCT method. Results.: Circulating EPCs were reduced and miR-126 expression was increased in DM1 compared to controls (0.030 [interquartile range [IQR], 0.020–0.050] vs. 0.060 [IQR, 0.030–0.110], P = 0.004; 1.740 [IQR, 0.890–4.120] vs. 0.990 [IQR, 0.487–3.015], P = 0.047 respectively) without differences between patients with and without DR. Patients with DR had higher expression of miR-221 than those without DR (1.405 [IQR, 0.820–2.867] vs. 0.915 [IQR, 0.507–1.292], P = 0.019) without differences among degrees of DR. Circulating EPCs were reduced in patients on statins (0.010 [IQR, 0.010–0.050] vs. 0.045 [IQR, 0.020–0.087], P = 0.008), and miR-221 expression increased in patients on angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blocker (ARB) II (1.430 [IQR, 1.160–2.705] vs. 1.000 [IQR, 0.520–1.330], P = 0.021) compared to those without treatment. MicroRNA-126 expression was associated with body mass index (BMI; ρ = −0.267, P = 0.026) and diastolic blood pressure (ρ = −0.267, P = 0.034). MicroRNA-221 was associated with triglyceride concentration (ρ = 0.296, P = 0.012). Conclusions.: Circulating EPCs were reduced and miR-126 expression was increased in DM1 compared to controls. Patients with DR had higher expression of miR-221 than those without DR. The identification of biomarkers of diabetic complications might be useful for monitoring disease progression and potential therapeutic targets.